Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cardiovascular disease

Atherosclerosis

IL-17

Studies in patient samples, human cell culture and mice suggest upregulation of IL-17 signaling could help reduce the risk of cardiovascular events. In 132 human atherosclerotic plaques, transcriptome analysis identified a correlation between levels of IL-17, fibrous collagen and a marker of smooth muscle cells. In cultured human vascular smooth muscle cells, IL-17 increased abundance of fibrous collagen compared with no treatment. In a mouse model of atherosclerosis, an anti−Il-17 antibody decreased the size of fibrous caps and stability of atherosclerotic plaques compared with a nonspecific antibody. Planned work includes investigation of other molecules in the IL-17 signaling pathway as potential therapeutic targets to help stabilize atherosclerotic plaques.

SciBX 6(31); doi:10.1038/scibx.2013.826
Published online Aug. 15, 2013

Unpatented; unlicensed; available for partnering

Gisterå, A. et al. Sci. Transl. Med.; published online July 31, 2013;
doi:10.1126/scitranslmed.3006133
Contact: Göran K. Hansson, Karolinska Institute, Stockholm, Sweden
e-mail:

goran.hansson@ki.se
Contact: Richard A. Flavell, Yale School of Medicine, New Haven, Conn.
e-mail:

richard.flavell@yale.edu